{"schema_version":"secwatch.filing_event.v1","accession":"0001200375-23-000009","form_type":"8-K","ticker":"CDXS","cik":"0001200375","company_name":"CODEXIS, INC.","filed_at":"2023-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.082519+00:00","generated_at":"2026-06-19T01:39:49.290523+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Codexis reports FY2022 revenue $138.6M (+32% YoY); net loss $33.6M; provides 2023 guidance $63-68M ex-PAXLOVID","bullets":["FY2022 total revenue $138.6M (+32% YoY); ex-PAXLOVID revenue $63.2M (-10% YoY). Net loss $33.6M ($0.51/share) vs $21.3M loss in 2021.","Q4 2022 revenue $30.4M (+24% YoY); net loss $12.6M ($0.19/share) vs $10.2M loss in Q4 2021.","2023 guidance: total revenue $63-68M, product revenue $35-40M (both ex-PAXLOVID); gross margin 68-73%. Cash runway through end 2024.","Roche exercised ROFN on newly engineered DNA ligase for NGS; interim Phase 1 data for CDX-7108 (EPI) with Nestlé showed improved lipid absorption.","Upcoming IND filings: Nestlé for PKU (CDX-6114) H2 2023; Nestlé for EPI (CDX-7108) by end 2023; Takeda for Fabry as soon as late 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001200375-23-000009","json":"https://secwatch.observer/filing/0001200375-23-000009.json","markdown":"https://secwatch.observer/filing/0001200375-23-000009.md","text":"https://secwatch.observer/filing/0001200375-23-000009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1200375/000120037523000009/0001200375-23-000009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1200375/000120037523000009/cdxs-20230223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T01:39:49.290523+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"88ecd8b03bed671a2dd5ce7bf2ab2089b6760baa","claim":"CODEXIS, INC. reported financial results for the fourth quarter ended December 31, 2022.","evidence_excerpt":"On February 23, 2023, Codexis, Inc. (the “Company”) announced its financial results for the fourth quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1200375/000120037523000009/0001200375-23-000009-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"bf57a464b5ba9d20bfe18ccb5f51f58efc7987c0","claim":"CODEXIS, INC. reported the fiscal year ended December 31, 2022 results: revenue $138.6 million.","evidence_excerpt":"Total revenues for fiscal year 2022 were $138.6 million, an increase of 32% from $104.8 million the prior year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1200375/000120037523000009/0001200375-23-000009-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2022"},{"label":"Revenue","value":"$138.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}